19 completed. 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 19 |
Follow Chronic Plaque Psoriasis: new trials by email Literature Review of Chronic Plaque Psoriasis trials Research Report on Chronic Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 133 | 2023-10-31 | 2026-06-26 |
| Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis Tildrakizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis | Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 99 | 2021-05-13 | 2026-04-01 |
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Topical roflumilast - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 337 | 2020-02-12 | 2026-09-09 |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Roflumilast 0.3% cream, Vehicle Cream - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 439 | 2019-12-20 | 2022-12-07 |
| Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis ARQ-151 0.3% cream, ARQ-151 vehicle cream - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 442 | 2019-12-17 | 2022-12-07 |
| A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 172 | 2018-12-20 | 2025-07-14 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 1353 | 2018-09-05 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Secukinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 743 | 2018-06-13 | 2026-04-15 |
| A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 435 | 2018-02-05 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Adalimumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 478 | 2018-01-26 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Ustekinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 567 | 2017-12-06 | 2026-04-15 |
| Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis M923, Humira - Chronic Plaque Psoriasis, Psoriasis | Phase 3 | Completed | Momenta Pharmaceuticals, Inc. | 572 | 2015-09-01 | 2018-10-17 |
| Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis Placebo, secukinumab (AIN457), etanercept - Chronic Plaque Psoriasis | Phase 3 | Completed | Novartis Pharmaceuticals | 1306 | 2011-06-01 | 2021-01-05 |
| Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment adalimumab, Calcipotriol/Betamethasone Ointment, placebo (vehicle ointment) - Chronic Plaque Psoriasis | Phase 3 | Completed | Abbott | 730 | 2007-11-01 | 2011-04-13 |
| Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis Cyclosporine A microemulsion, Placebo - Chronic Plaque Psoriasis | Phase 3 | Completed | Novartis Pharmaceuticals | 243 | 2006-05-01 | 2011-08-09 |
| A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate alefacept, placebo - Chronic Plaque Psoriasis | Phase 3 | Completed | Astellas Pharma Inc | 195 | 2003-10-01 | 2014-08-26 |
| A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis alefacept - Chronic Plaque Psoriasis | Phase 3 | Completed | Astellas Pharma Inc | 78 | 2003-07-01 | 2014-08-26 |
| Safety and Tolerability of Repeat Courses of IM Alefacept Alefacept - Chronic Plaque Psoriasis | Phase 3 | Completed | Biogen | 400 | 2002-12-01 | 2023-08-23 |
| Topical Vitamin B12 in Chronic Plaque Psoriasis topical vitamin B12 - Chronic Plaque Psoriasis | Phase 3 | Completed | Ruhr University of Bochum | 48 | 2001-01-01 | 2006-07-10 |
Psoriasis (10) · Arthritis, Psoriatic (2) · Dermatitis (1)
Skin Diseases (10) · Skin Diseases, Papulosquamous (10) · Skin and Connective Tissue Diseases (10) · Arthritis (2) · Bone Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Spinal Diseases (2) · Spondylarthritis (2) · Spondylarthropathies (2) · Spondylitis (2)
bimekizumab (7) · Adalimumab (3) · Alefacept (3) · Roflumilast (2) · secukinumab (2) · Cyclosporine (1) · Etanercept (1) · Ustekinumab (1) · Vitamin B 12 (1) · betamethasone dipropionate, calcipotriol drug combination (1) · calcipotriene (1) · tildrakizumab (1)
UCB Biopharma SRL (7) · Arcutis Biotherapeutics, Inc. (3) · Astellas Pharma Inc (2) · Novartis Pharmaceuticals (2) · Abbott (1) · Biogen (1) · Momenta Pharmaceuticals, Inc. (1) · Ruhr University of Bochum (1) · Sun Pharmaceutical Industries Limited (1)
United States (15) · Canada (14) · Germany (11) · Australia (7) · Poland (7) · United Kingdom (7) · Belgium (6) · Hungary (5) · Italy (5) · France (4) · Russia (4) · South Korea (4) · Austria (3) · Netherlands (3) · Spain (3)
David Berk, MD (2) · Barry Ticho, MD (1) · John Caminis, MD (1) · Kenneth Gordon, MD (1) · Peter Altmeyer, Prof. Dr. (1)
PMID 39578348, PMID 41060492, PMID 41800601, PMID 35544084, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 41580158, PMID 34260044, PMID 36125472, PMID 36422852, PMID 36689515, PMID 38588819, PMID 41134450, PMID 23178916, PMID 25007392, PMID 26267726, PMID 27573260, PMID 27576559, PMID 30972746, PMID 33549192, PMID 33549193, PMID 33748660, PMID 33891379, PMID 33891380, PMID 34001692, PMID 34110605, PMID 34471992, PMID 35133113, PMID 35305260, PMID 36648594, PMID 37182701, PMID 37341961, PMID 39285121, PMID 39862230, PMID 40156698, PMID 40788331, PMID 41678327, PMID 41706476
2016 (4), 2017 (1)